Friday 2 October

Location: Room S3

Topic 2: NAMs – From Predictivity to Transability
08:45 - 09:30 | Keynote  - A Pathologist’s Role in the Adoption of NAMs: Should We Lead, Follow, or Step Aside? - Brian R. Berridge
09:30 - 09:50 |  Insight on regulatory policy and consortia - Imen Bousnina and Nadine Stokar-Regenscheit
09:50 - 10:00 | Q&A1
10:00 - 10:30 |  Pathologist's toolbox for in vitro model characterization and toxicologic pathology evaluation - Nadine Stokar-Regenscheit

10:30 - 11:00 | Morning Coffee Break | Room S4 - Exhibition

11:00 - 11:30 |  Example 1: Organoids for discovery - pos vs. neg experiences when compared to animal models. lung, GIT, skin - Pharmaceutic example - Dinesh Bangari
11:30 - 11:55 |  Example 2: NAMs project looking at the effect of known toxicants in 3D airway models in which we are using path eval and image analysis as key endpoints - Agrochemicals example - James Baily
11:55 - 12:15 |  Example 3: Navigating Complexity in Modern Toxicology: the Role of omics in short-term in vivo studies - Agrochemicals example - David Rouquie
12:15 - 12:35 |  Example 4: Kidney Model - Pharmaceutic example - Steven Laing
12:35 - 12:50 |  Example 5: New Approach Methodologies (NAMs): Leveraging the complementary strengths of tissue cross-reactivity and cell-based protein array technologies to enhance the weight of evidence supporting a test article’s safety profile - James T Raymond
12:50 - 13:00 | Q&A2

13:00 - 13:05 | Closing Ceremony

13:05 - 14:00 | Lunch Break | Room S4 - Exhibition